Inactive Instrument

News 3D Signatures Inc Toronto S.E.

Equities

CA88555C1077

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Telo Genomics Corp. announced that it has received CAD 0.65 million in funding	06-20	CI
Telo Genomics' Myeloma Test Accepted as Lab Developed Test by College of American Pathologists	06-18	MT
Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP	06-18	NE
Telo Genomics Corp. Announces Results of Development, Validation and Implementation of its Machine Learning and Artificial Intelligence Modules, Use in its TeloView Myeloma Diagnostic Tests	06-12	CI
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024	06-12	NE
Telo Genomics Corp. announced that it expects to receive CAD 0.6 million in funding	06-03	CI
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology	05-30	NE
Telo Genomics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-28	CI
Telo Genomics Corp. Signs Collaboration Agreement with Emery Pharma	05-15	CI
Telo Genomics and Emery Pharma Announce Collaboration	05-15	NE
Telo Genomics Receives Accreditation from College of American Pathologists	04-10	MT
Telo Genomics Receives Accreditation from College of American Pathologists	04-10	NE
Telo Genomics Corp. Receives Accreditation from College of American Pathologists	04-10	CI
Telo Genomics' MRD Clinical Trial Expands into Multi-Center Trial; Shares up 9.5%	04-02	MT
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial	04-02	NE
Telo Genomics Corp. Announces Patient Recruitment for Its Minimal Respiratory Disease Clinical Trial Has Been Initiated, with Several Patient Samples Received and Processed to Date	04-02	CI
Telo Genomics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-27	CI
Telo Genomics Corp. Initiates MRD Clinical Trial for Multiple Myeloma Patients	02-13	CI
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients	02-13	NE
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US	01-30	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News 3D Signatures Inc Toronto S.E.

Equities

CA88555C1077

Summary

Filters